Loading...
IVCR.Q logo

Invacare CorporationOTCPK:IVCR.Q Rapport sur les actions

Capitalisation boursière US$512.8k
Prix de l'action
n/a
1Y-99.1%
7D-10.6%
1D-6.9%
Valeur du portefeuille
Voir

Invacare Corporation

OTCPK:IVCR.Q Rapport sur les actions

Capitalisation boursière : US$512.8k

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Invacare (IVCR.Q) Aperçu de l'action

Invacare Corporation, together with its subsidiaries, designs, manufactures, distributes, and exports medical equipment for use in home health care, retail, and extended care markets worldwide. Plus de détails

IVCR.Q analyse fondamentale
Score flocon de neige
Évaluation2/6
Croissance future0/6
Performances passées0/6
Santé financière1/6
Dividendes0/6

IVCR.Q Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

NEW501,452 members

Join community and earn perks

Gain real feedbackFrom our editorial team, personally. Not silence.
Grow your followingReal investors. The kind who actually invest, not scroll past.
Unlock free accessFree premium subscription for consistent and quality authors.
BL
BlackGoat
IN
Investingwilly
RO
RockeTeller
AG
Agricola
501,452 investors already sharing narratives

Invacare Corporation Concurrents

Historique des prix et performances

Résumé des hausses, des baisses et des variations du cours de l'action pour la période du 1er janvier au 31 décembre 2009 Invacare
Historique des cours de bourse
Prix actuel de l'actionUS$0.013
Plus haut sur 52 semainesUS$1.64
Plus bas sur 52 semainesUS$0.011
Bêta0.51
Variation sur 1 mois-10.00%
Variation sur 3 mois-62.60%
Variation sur 1 an-99.09%
Variation sur 3 ans-99.77%
Variation sur 5 ans-99.92%
Évolution depuis l'introduction en bourse-99.49%

Nouvelles et mises à jour récentes

Recent updates

Seeking Alpha Feb 01

Invacare falls on bankruptcy filing

Medical equipment maker Invacare Corporation (NYSE:IVC) lost ~20% in the pre-market trading Wednesday after announcing that the company and two U.S.-based subsidiaries filed for voluntary Chapter 11 bankruptcy. The cases, filed in the Bankruptcy Court for the Southern District of Texas, do not include its international operations and are not expected to impact the company’s ability to serve its global clientele, Invacare (IVC) said. The bankruptcy cases follow a financial restructuring agreement the company inked with almost all of its debt holders and most of the convertible noteholders. The deal, known as Restructuring Support Agreement, allows Invacare (IVC) to reduce its debt by ~$240M and provides the company with $60M equity capital to repay certain debt and fund its transformation plan. “The company expects to emerge with significantly less debt on its balance sheet and will secure additional liquidity to support long-term growth,” Invacare’s (IVC) recently appointed Chief Executive Geoff Purtill noted.
Seeking Alpha Dec 27

Invacare announces additional draw of $5.5M term loans

Invacare (NYSE:IVC) announced additional draw of $5.5M of term loans under its credit agreement. The company said certain funds will be managed by Highbridge Capital Managed. The company will use the proceeds of the additional draw for general corporate purposes, it said. About $14M of additional liquidity remains available under the Amended Highbridge Credit Agreement, subject to satisfaction of certain conditions set forth therein.
Article d’analyse Nov 14

Invacare Corporation (NYSE:IVC) Analysts Just Slashed Next Year's Estimates

Market forces rained on the parade of Invacare Corporation ( NYSE:IVC ) shareholders today, when the analysts...
Seeking Alpha Nov 07

Invacare GAAP EPS of -$0.92, revenue of $170.4M

Invacare press release (NYSE:IVC): Q3 GAAP EPS of -$0.92. Revenue of $170.4M (-24.0% Y/Y). Gross margin was 18.4%, a decrease of 850 basis points, including 510 basis points of decline related to the write-down of respiratory inventory as a result of the decision to discontinue production of respiratory products. SG&A expense decreased 1.4% to $55.4 million, and constant currency SG&A increased 4.5%. Operating loss was $33.4 million compared to a loss of $24.8 million. Adjusted EBITDA loss was $11.8 million, compared to positive $8.0 million. Free cash flow usage was $20.5 million compared to usage of $6.1 million.
Seeking Alpha Sep 29

Invacare receives non-compliance letter from NYSE

Invacare (NYSE:IVC) said on Thursday it had received notice from the New York Stock Exchange that it was not in compliance with the NYSE listed company manual as the average closing price was less than $1 per share over a consecutive 30 trading-day period. The company plans to notify the NYSE by October 7 on its plan to return to compliance with the NYSE continued listing standard. The company can regain compliance at any time within the six-month period. The company is required to have a closing share price of at least $1 over a consecutive 30 trading-day period. The company intends to consider available alternatives, including, but not limited to, a reverse stock split, subject to shareholder approval no later than at the company’s next annual meeting of shareholders.
Seeking Alpha Aug 29

Invacare names Geoffrey Purtill as interim president and executive chief

Invacare (NYSE:IVC) on Monday has named Geoffrey P. Purtill as the company's interim president and chief executive officer, succeeding departing chairman, president and CEO Matthew E. Monaghan. The transition is effective Aug. 28, 2022. Geoffrey P. Purtill had been serving as the Invacare's senior vice president and general manager, EMEA and APAC.  "We welcome Geoff who has distinguished himself throughout his tenure with Invacare. The Board has full confidence that he has the right skillset and industry experience to lead the company through this transition as we search for a permanent successor who can accelerate the achievement of our objectives," said Cliff Nastas, Invacare’s lead independent director. In addition, the Board has announced the appointment of Michael J. Merriman as its director and non-executive Chairman. Merriman previously served as chair of the company's audit committee from 2014 to 2018. "As the independent Chairman of the Board, Merriman succeeds Cliff Nastas as the company's lead independent director," report.  IVC stock jumps 9% in premarket on Monday to trade at $0.94 vs 52-week level of $0.80 to $8.73.
Seeking Alpha Aug 23

Invacare adds two new directors after deal with largest investor Azurite

Medical equipment maker Invacare Corporation (NYSE:IVC) has appointed two new directors with immediate effect as part of a corporation agreement with its largest shareholder, Azurite Management LLC, which owns more than 10% of IVC stock. The new directors, Steven H. Rosen and Edward F. Crawford will replace Julie A. Beck and Stephanie L. Fehr, who resigned from the board on Aug. 22. Mr. Rosen is the Co-Founder, and Co-Chief Executive of Ohio-based private equity firm Resilience Capital Partners LLC. Crawford, a former U.S. ambassador to Ireland from 2019 to 2021, currently serves Resilience as a Member of its Board of Advisors. As part of the deal, IVC has agreed to set up a five-member Strategy and Operational Improvement Committee comprising the new appointees. The terms of the corporation agreement include certain standstill provisions which, among other things, will bar Azurite from raising its IVC stake above 19.9%.
Article d’analyse Apr 30

Returns Are Gaining Momentum At Invacare (NYSE:IVC)

If you're not sure where to start when looking for the next multi-bagger, there are a few key trends you should keep an...
Article d’analyse Jan 27

Invacare (NYSE:IVC) Use Of Debt Could Be Considered Risky

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Article d’analyse Dec 01

Returns On Capital Are Showing Encouraging Signs At Invacare (NYSE:IVC)

Finding a business that has the potential to grow substantially is not easy, but it is possible if we look at a few key...
Article d’analyse Sep 30

Here's Why Invacare (NYSE:IVC) Is Weighed Down By Its Debt Load

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Article d’analyse Aug 06

When Should You Buy Invacare Corporation (NYSE:IVC)?

Invacare Corporation ( NYSE:IVC ), might not be a large cap stock, but it saw a decent share price growth in the teens...
Article d’analyse May 14

Increases to CEO Compensation Might Be Put On Hold For Now at Invacare Corporation (NYSE:IVC)

In the past three years, the share price of Invacare Corporation ( NYSE:IVC ) has struggled to grow and now...
Article d’analyse May 03

Returns On Capital Are Showing Encouraging Signs At Invacare (NYSE:IVC)

If you're not sure where to start when looking for the next multi-bagger, there are a few key trends you should keep an...
Article d’analyse Mar 03

Invacare Corporation's (NYSE:IVC) Path To Profitability

We feel now is a pretty good time to analyse Invacare Corporation's ( NYSE:IVC ) business as it appears the company may...
Article d’analyse Feb 05

Invacare (NYSE:IVC) Has A Somewhat Strained Balance Sheet

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...
Article d’analyse Jan 10

What Can The Trends At Invacare (NYSE:IVC) Tell Us About Their Returns?

If we want to find a stock that could multiply over the long term, what are the underlying trends we should look for...
Article d’analyse Dec 14

Invacare's(NYSE:IVC) Share Price Is Down 48% Over The Past Five Years.

It is a pleasure to report that the Invacare Corporation ( NYSE:IVC ) is up 33% in the last quarter. But over the last...
Article d’analyse Nov 23

Invacare Corporation's (NYSE:IVC) Shift From Loss To Profit

With the business potentially at an important milestone, we thought we'd take a closer look at Invacare Corporation's...

Rendement pour les actionnaires

IVCR.QUS Medical EquipmentUS Marché
7D-10.6%5.7%-0.7%
1Y-99.1%-17.8%20.3%

Rendement vs Industrie: IVCR.Q a sous-performé le secteur US Medical Equipment qui a rapporté -17.8 % au cours de l'année écoulée.

Rendement vs marché: IVCR.Q a sous-performé le marché US qui a rapporté 20.3 % au cours de l'année écoulée.

Volatilité des prix

Is IVCR.Q's price volatile compared to industry and market?
IVCR.Q volatility
IVCR.Q Average Weekly Movement28.2%
Medical Equipment Industry Average Movement8.6%
Market Average Movement7.3%
10% most volatile stocks in US Market16.8%
10% least volatile stocks in US Market3.2%

Cours de l'action stable: Le cours de l'action de IVCR.Q a été volatil au cours des 3 derniers mois par rapport au marché US.

Volatilité au fil du temps: La volatilité hebdomadaire de IVCR.Q ( 28% ) est restée stable au cours de l'année écoulée, mais reste supérieure à 75 % des actions de US.

À propos de l'entreprise

FondéeSalariésPDGSite web
18852,800Geoff Purtillwww.invacare.com

Invacare Corporation Résumé des fondamentaux

Comment les bénéfices et les revenus de Invacare se comparent-ils à sa capitalisation boursière ?
IVCR.Q statistiques fondamentales
Capitalisation boursièreUS$512.81k
Bénéfices(TTM)-US$101.07m
Recettes(TTM)US$741.73m
0.0x
Ratio P/S
0.0x
Ratio P/E

Le site IVCR.Q est-il surévalué ?

Voir Juste valeur et analyse de l'évaluation

Bénéfices et recettes

Principales statistiques de rentabilité tirées du dernier rapport sur les bénéfices (TTM)
IVCR.Q compte de résultat (TTM)
RecettesUS$741.73m
Coût des recettesUS$557.69m
Marge bruteUS$184.04m
Autres dépensesUS$285.12m
Les revenus-US$101.07m

Derniers bénéfices déclarés

Dec 31, 2022

Prochaine date de publication des résultats

s/o

Résultat par action (EPS)-2.66
Marge brute24.81%
Marge bénéficiaire nette-13.63%
Ratio dettes/capitaux propres436.8%

Quelles ont été les performances à long terme de IVCR.Q?

Voir les performances historiques et les comparaisons

Analyse de l'entreprise et données financières

DonnéesDernière mise à jour (heure UTC)
Analyse de l'entreprise2023/05/05 05:45
Cours de l'action en fin de journée2023/05/05 00:00
Les revenus2022/12/31
Revenus annuels2022/12/31

Sources de données

Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.

PaquetDonnéesCadre temporelExemple de source américaine *
Finances de l'entreprise10 ans
  • Compte de résultat
  • Tableau des flux de trésorerie
  • Bilan
Estimations consensuelles des analystes+3 ans
  • Prévisions financières
  • Objectifs de prix des analystes
Prix du marché30 ans
  • Cours des actions
  • Dividendes, scissions et actions
Propriété10 ans
  • Actionnaires principaux
  • Délits d'initiés
Gestion10 ans
  • L'équipe dirigeante
  • Conseil d'administration
Principaux développements10 ans
  • Annonces de l'entreprise

* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.

Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.

Modèle d'analyse et flocon de neige

Les détails du modèle d'analyse utilisé pour générer ce rapport sont disponibles sur notre page Github, nous proposons également des guides pour apprendre à utiliser nos rapports et des tutoriels sur YouTube.

Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.

Indicateurs de l'industrie et du secteur

Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.

Sources des analystes

Invacare Corporation est couverte par 7 analystes. de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.

AnalysteInstitution
Robert LabickCJS Securities, Inc.
Constantine DavidesD. Boral Capital LLC.
Matthew MishanKeyBanc Capital Markets Inc.